Complix

FlandersBio on Twitter

Roche & reMYND enter into a strategic alliance to develop disease-modifying treatments for Parkinson’s and Alzheimer’s: http://tiny.cc/vgsr5

posted 10 hours ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.complix.be
Email:
Phone: +32 9 241 57 14
FlandersBio Member
More address details

Business Focus

Complix develops scaffold therapeutics. An early-stage biotech company developing therapeutic proteins for drug, medical device and bioprocessing applications. Complix manages an in-house drug development programme available for outlicensing, and a service department offering contract research.

Company Profile

Complix is an early-stage biotech company developing therapeutic proteins for drug, medical device and bioprocessing applications. Complix manages an in-house drug development programme available for out-licensing, and a service department offering contract research.

Science & Technology or Services

The alpha-body™ is a protein scaffold with exquisite physical properties. Its triple-α-helical coiled coil architecture renders it extremely stable and highly engineerable. The coiled coil part is extendable, making it a truly scalable scaffold. The α-helical segments being cleverly adjoined, alpha-bodies can be produced recombinantly as soluble single-chain molecules. They form ideal instruments for next-generation protein-based therapeutics. The alpha-body technology allows the development of specific binders with high affinity against a wide range of biomolecules. The alpha-body platform technology is the preferred tool for efficient binder discovery, thanks to the extreme stability and engineerability of the alpha-body scaffold.